BARDA is collaborating with partners from the Public Health Emergency Medical Countermeasures Enterprise to address medical countermeasure needs for the Zika response both domestically and globally. BARDA is working to transition medical countermeasure candidates from early development into advanced research and development and then towards FDA approval.
BARDA has developed four strategic goals to address the medical countermeasure needs for the Zika response:
- Prevent Zika virus infection through new vaccines
- Detect acute and previous Zika virus infections through new rapid diagnostics
- Ensure a blood supply safe from Zika virus through use of screening tests for donated blood and virus inactivation in blood products
- Activate our National Medical Countermeasure Response Infrastructure to help medical countermeasure developers
To implement these strategic goals, BARDA is building on existing and new partnerships and lessons learned from the H1N1 and Ebola responses.
Partner with BARDA
BARDA is interested in learning more about actual and potential medical countermeasures for Zika. Product developers who are interested in partnering with BARDA on medical countermeasures to fight Zika virus infection can submit their ideas to us using the following mechanisms:
